The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / MicroRNA-Based Therapeutics Hold Promise Against Lupus, Other Rheumatic Diseases Note Experts at the ACR/ARHP’s 2013 Annual Meeting

MicroRNA-Based Therapeutics Hold Promise Against Lupus, Other Rheumatic Diseases Note Experts at the ACR/ARHP’s 2013 Annual Meeting

April 2, 2014 • By Susan Bernstein

  • Tweet
  • Email
Print-Friendly Version / Save PDF

You Might Also Like
  • Switches That Regulate Gene Expression Offer Better Understanding of Rheumatic Disease Say Experts at the 2013 ACR/ARHP Annual Meeting
  • Research Reveals Clues Into Inflammatory Process of Crystal Arthropathies Note Experts at the 2013 ACR/ARHP Annual Meeting
  • Causes of Alopecia Can Vary Among Patients with Systemic Disease Say Experts at the 2013 ACR/ARHP Annual Meeting
Explore This Issue
April 2014
Also By This Author
  • FDA Provides 2020 Rheumatology Drug Update

SAN DIEGO—In a session titled, In Vivo Administration of MiR-146a Protects C57BL/6 Mice from Pristane-Induced Pulmonary Hemorrhage via Suppressing Type 1 Interferon Response, Nan Shen, MD, professor of medicine and director, Shanghai Institute of Rheumatology, Renji Hospital, Jiao Tong University School of Medicine, Shanghai, China, presented the Rheumatology Research Foundation Edmond L. Dubois, MD, Memorial Lectureship at the 2013 ACR/ARHP Annual Meeting. (Editor’s note: This session was recorded and is available via ACR SessionSelect at www.rheumatology.org.)

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Along with reviewing previous studies that have shown the crucial role of microRNAs (miRNAs) for human lupus, and in particular the role of a novel functional variant in the microRNA-146a gene, Dr. Shen presented findings from a current study that explored a therapeutic potential of miRNA-146a in a murine model of lupus.

“Growing evidence shows deregulation and dysfunction of miRNAs in human lupus and lupus-like mice model, and that miRNAs are associated with prognosis and progression of several human diseases and may serve as future targets for gene therapy,” Dr. Shen said. “Indeed, the clear importance of miRNA to disease expression is striking in both man and mouse, and several clinical trials are now underway using [a] miRNA inhibition approach for treating several common diseases.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

MicroRNAs—Some Background

“MicroRNAs represent a large class of small non-coding RNAs that ubiquitously exist in a broad range of species from worms to mammals, which function as an important class of molecular mediators functioning in post-transcriptional regulation, [and] play a crucial role in diverse biological processes, including regulation of immune response and involvement in autoimmunity,” said Dr. Shen.

Figure 1 illustrates miRNAs as novel regulators of the disease pathways of lupus. In his talk, Dr. Shen provided data from previous studies he and his colleagues have done to dissect the molecular mechanisms underlining the genetic and epigenetic control of lupus development. In these studies, they were able to show that overexpression of miRNA-146a in the peripheral blood mononucleated cells (PBMCs) from patients with systemic lupus erythematosus (SLE) suppressed activation of the type 1 interferon (IFN) pathway.1,2,3 This finding suggested to Dr. Shen and his colleagues that manipulation of miRNA-146a levels may be a useful therapeutic intervention in SLE, and prompted the current study to investigate the therapeutic potential of miRNA-146a for lupus intervention by an induced murine model of SLE.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE
Figure 1: MicroRNA : Novel Regulators of Lupus disease pathways
click for large version
Figure 1: MicroRNA : Novel Regulators of Lupus disease pathways

Study: Therapeutic Potential of miR-146a in Induced Murine Model of Lupus

In their current study, Shen and colleagues used pristane-induced lupus, a well-established SLE murine model featuring abnormal activation of IFN pathway and an unusually high incidence of pulmonary capillaritis. Mice were intravenously injected with MiRNA-146a or phosphate-buffered saline (PBS) via lateral tail veins. Real-time polymerase chain reaction (PCR) or gene expression profile analysis was used to evaluate the peripheral blood drawn 3, 7 and 14 days after pristane injection. Mice were categorized into three groups for comparison: those receiving three consecutive injections of PBS (control group; n=9), those receiving miRNA-146a three days before a single intraperitoneal injection of pristane (prevention group; n=19), and those receiving miRNA-146a seven days after a single intraperitoneal injection of pristane (treatment group; n=10). The development of pulmonary hemorrhage was confirmed two weeks after the pristane injection using a hematoxylin and eosin (HE) stain.

Pages: 1 2 | Single Page

Filed Under: Conditions, Meeting Reports, SLE (Lupus) Tagged With: ACR/ARHP Annual Meeting, gene therapy, Lupus, microRNA, miRNA, Research, Rheumatic Disease, Systemic lupus erythematosusIssue: April 2014

You Might Also Like:
  • Switches That Regulate Gene Expression Offer Better Understanding of Rheumatic Disease Say Experts at the 2013 ACR/ARHP Annual Meeting
  • Research Reveals Clues Into Inflammatory Process of Crystal Arthropathies Note Experts at the 2013 ACR/ARHP Annual Meeting
  • Causes of Alopecia Can Vary Among Patients with Systemic Disease Say Experts at the 2013 ACR/ARHP Annual Meeting
  • 2014 ACR/ARHP Annual Meeting: Super Proteins Eyed in Therapies for Rheumatic Diseases

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.